TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Apis Capital Advisors LLC

Apis Capital Advisors LLC reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 23.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,000 shares of the company’s stock after selling 12,400 shares during the quarter. TransMedics Group comprises approximately 4.4% of Apis Capital Advisors LLC’s portfolio, making the stock its 8th biggest holding. Apis Capital Advisors LLC owned approximately 0.12% of TransMedics Group worth $6,025,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Wasatch Advisors LP purchased a new stake in TransMedics Group in the 1st quarter worth approximately $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new position in TransMedics Group in the second quarter valued at $39,862,000. First Light Asset Management LLC increased its stake in TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the last quarter. Hood River Capital Management LLC acquired a new stake in TransMedics Group in the 2nd quarter worth about $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new stake in TransMedics Group in the 2nd quarter worth about $16,086,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.6 %

NASDAQ:TMDX opened at $165.00 on Monday. The business’s 50-day moving average is $155.65 and its two-hundred day moving average is $129.63. The firm has a market capitalization of $5.43 billion, a PE ratio of -485.29 and a beta of 1.99. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s revenue was up 117.7% on a year-over-year basis. During the same period last year, the business posted ($0.03) EPS. Research analysts predict that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,247 shares of company stock valued at $9,650,880. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMDX. Needham & Company LLC began coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective on the stock. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Morgan Stanley increased their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price on the stock. Finally, Stephens upped their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $171.44.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.